Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

In the realm of gene-editing therapies, Vertex has launched Casgevy, an ex-vivo gene-edited cell therapy for the severe blood ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

The FDA approved Vertex Pharmaceuticals’ gene therapy Casgevy for treating beta thalassemia, an inherited blood disease that leads to low levels of functioning hemoglobin. Last month ...

Vertex Pharmaceuticals Inc. (NASDAQ ... The company is also making progress with Casgevy, its gene therapy treatment. While the launch is in its early stages, with over 50 treatment centers ...

Learn how CASGEVY, the first NHS-approved CRISPR gene therapy, treats sickle cell disease through a revolutionary genetic ...

Vertex Pharmaceuticals (Nasdaq ... patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute ...

Additionally, shares of Vertex Pharmaceuticals have surged 14.7% ... patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY, creating a positive sentiment, and its shares jumped 5.3% ...